REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 382 participants.
Also called NCT03618095
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 382 participants
- Sponsor
- Registry
-
NCT03618095
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia
- Registry status
- Terminated
Technical summary
Registry record NCT03618095. Non-randomized; no masking; primary purpose treatment. Start 2019-01-14 (actual); primary completion 2021-03-30 (actual). Results posted on 2022-12-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
- Acronym
- REPRISE IV
- Condition
- Aortic Valve Stenosis
- Intervention (Device)
- LOTUS Edge Valve System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct03618095- Content hash
74b61e5d76fb03b4a739d83764c00ef96891f0bafc30a73639ef66a8c8a54a5e